CEVEC Pharmaceuticals signed a non-exclusive agreement with Biogen for the use of CEVEC’s proprietary Elevecta technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy. The deal will afford Biogen the rights to use the technology across their portfolio of gene therapy products. Under the license, CEVEC is eligible for technology access and milestone fees, including clinical development and commercial milestones, as well as royalties on net sales of products.

“We are delighted to strengthen our collaboration with Biogen with this license agreement, enabling them to use [our technology] as a platform and to efficiently manufacture AAV vectors for their growing gene therapy portfolio,” said Nicole Faust, PhD, CEO of CEVEC. “Over the last several years we have seen a strong need across Pharma and Biotech companies to establish scalable and robust manufacturing technologies for AAV vectors. This agreement represents the next major step on our journey.”

This site uses Akismet to reduce spam. Learn how your comment data is processed.